Results 231 to 240 of about 145,978 (310)

The tryptophan prenyltransferase ComQ from Bacillus subtilis 168 can prenylate daptomycin at Trp1

The FEBS Journal, EarlyView.
ComQ168 from Bacillus subtilis 168 catalyzes C‐terminal tryptophan farnesylation of ComX to generate a competence‐inducing pheromone. Recombinant ComQ168 also modifies cyclic peptides, including Daptomycin, likely at the N‐terminal tryptophan. Structural modeling highlights a C‐terminal binding region, supporting substrate promiscuity and establishing ...
Yanli Xu, Maximilian J. L. J. Fürst, Oscar P. Kuipers   +2 more
wiley   +1 more source

PD0325901 alleviates thrombin-inhibited osteogenic differentiation through an IL-1β-activated feedback loop between MEK-Erk1/2 and NF-κB signal pathways: insights from bioinformatics and experimental verification. [PDF]

Front Immunol
Ge YS, Huang CM, Shen J, Meng TT, Zhao MJ, Yin JL, Huang XH, Chen LL, Luo JH, Zhai YQ, Du JW, Wang YL, Wang XZ, Sun PP, Ding DF.   +14 more
europepmc   +1 more source

RNF13 regulates the endolysosomal pathway through interaction with the small GTPase Arl8B

The FEBS Journal, EarlyView.
The E3 ubiquitin ligase RNF13 functions as a regulatory scaffold, organizing Arl8B‐dependent complexes and tuning downstream signaling that controls endolysosomal organization and trafficking. In this model, wild‐type RNF13 associates with Arl8B on endolysosomes, whereas Arl8B (E22D/F55A) or RNF13 (L244A) variants weaken complex assembly, potentially ...
Audrey M. Sénécal, Valérie C. Cabana, Antoine Y. Bouchard, Laurent Cappadocia, Marc P. Lussier   +4 more
wiley   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

In silico analysis of patient specific coagulation and flow effects on fibrin clot formation. [PDF]

Sci Rep
Cruts JMH, Rezaeimoghaddam M, Rachid A, Bontempi L, Arisz RA, van de Vosse FN, Gijsen FJH.   +6 more
europepmc   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half-Life FVIII versus Non-FVIII Therapies. [PDF]

Haemophilia
Garcia J, Yates SG, Sarode R, Young G, Zia A.   +4 more
europepmc   +1 more source

Performing Large‐Scale Genetic Analysis in the Bleeding Disorders Community

Haemophilia, EarlyView.
ABSTRACT Inherited bleeding disorders encompass a diverse group of conditions caused by genetic defects affecting coagulation factors, fibrinogen, von Willebrand factor, or platelet function. Despite major advances in quantitative and functional laboratory assays, a substantial diagnostic gap remains, particularly in patients with mild or atypical ...
Anna R. Blankstein, Sterre P. E. Willems, Saskia E. M. Schols, Rosanna Asselta, Gillian Lowe, Neil V. Morgan, Paula D. James   +6 more
wiley   +1 more source

Comparison of the Calibrated Automated Thrombogram Using Standard and Low Plasma Volumes in Dogs. [PDF]

Vet Clin Pathol
Phillips EM, Blois SL, Monteith G, Abrams-Ogg ACG, Wood RD, Cuq B.   +5 more
europepmc   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source